Economy‘High tide’ of Chinese biotech deals expected as US curbs threat fades: analysts
Analysts expect US-China biotech deals to flourish as Washington reportedly moves away from sweeping restrictions, giving Chinese healthcare firms a major boost after Beijing’s ambitious five-year sector plan. Nomura’s China healthcare research chief Jialin Zhang said China-US out-licensing deals would “ride on a high tide” in the favourable environment.
S
South China Morning Post★★☆☆☆2026-09-21 10:00Original
‘High tide’ of Chinese biotech deals expected as US curbs threat fades: analysts
Economy